This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Buying Bluebird's Blockbuster Potential at a Discount

It's not often an investor gets the opportunity to buy a biotech stock with two blockbuster indications in the pipeline and major catalysts only months away at such a discount.

Why I'm More Confident in Sarepta Than Ever Before

Biotech trader Dan Rosenblum believes the recent selloff in Sarepta is a tremendous buying opportunity.

Sarepta: Staying Long and Strong
Sarepta: Staying Long and Strong

04/25/13 - 09:25 AM EDT

Contributor Dan Rosenblum believes Sarepta's upside potential far outweighs the risk in the stock.

Sarepta Is Undervalued Even Without Eteplirsen Accelerated Approval

The exon-skipping drug technology is worth a lot more than just eteplirsen alone.

Insider Buying at Auxilium, Aveo Hints At Big Moves in 2013

Insiders at Auxilium and Aveo appear to be betting on turnarounds for both stocks in the next year.

Still Bullish on BioMarin, Lexicon Pharma

TheStreet contributor Dan Rosenblum explains why he still likes BioMarin and Lexicon Pharma.

Sunshine Heart: A Promising Treatment for Heart Failure Patients

Sunshine's C-Pulse is a heart-assist device for patients who fall between the cracks of current therapy.

Lexicon Pharma: Blockbuster Potential From A Diabetes Drug

Lexicons mid-stage diabetes drug blocks the reabsorption of blood sugar.

Biomarin: Four Clinical Trial Events to Watch Before Year End

TheStreet contributor Dan Rosenblum explains why Biomarin is a very busy biotech.

Nanosphere: A Low-Risk, High-Growth Diagnostic Stock

A hospital-based sepsis test is the launching pad for Nanosphere.

Page 1 of 2
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs